CBD and Sodium Propionate Enema Reduced Colitis Severity in New Study
- The study published in the Journal of Cannabis Research found that a rectal enema combining cannabidiol (CBD) and sodium propionate reduced disease severity in mice with ulcerative colitis more effectively than either treatment alone.
- Using a murine model of dextran sodium sulfate-induced colitis, researchers from Tel Aviv University tested various treatments including saline, hyaluronic acid, hyaluronic acid plus CBD, hyaluronic acid plus sodium propionate, and a combination of CBD and sodium propionate.
- The combination treatment led to a 34.7% increase in colon length and a more sustained reduction in disease activity scores, along with reduced body weight loss compared to controls and single treatments.
- Safety assessments showed no adverse effects like hemorrhages or fibrin deposits, supporting the potential for further clinical research on this combined enema therapy for ulcerative colitis.
A recent study published in Journal of Cannabis Research found that a rectal enema combining cannabidiol (CBD) and sodium propionate reduced disease severity in mice with ulcerative colitis, performing better than either treatment used on its own.
Researchers from Tel Aviv University examined the experimental treatment in a murine model of dextran sodium sulfate-induced colitis, a commonly used method for studying ulcerative colitis. The condition is marked by inflammation in the colon, disruption of the intestinal lining, and immune dysfunction.
In the study, mice were given one of several daily rectal treatments between day 4 and day 11: saline, hyaluronic acid as a vehicle, hyaluronic acid plus CBD, hyaluronic acid plus sodium propionate, or a combination of CBD and sodium propionate. The goal was to determine whether pairing the two compounds could provide stronger anti-inflammatory and protective effects than either one alone.
The combination treatment produced the strongest results. Researchers found that colon length increased by 34.7% in the combination group compared to the saline control, a significantly greater improvement than what was seen with CBD or sodium propionate alone. The mice given the dual formulation also showed a sharper and more sustained drop in disease activity scores beginning on day 6, with superior outcomes by day 11.
Body weight loss, another marker of worsening disease, was also reduced in the combination group, with statistically significant differences appearing from day 6 onward. Histopathological analysis found lower scores in the combination group, along with less neutrophil infiltration and less mucosal damage, although those differences did not reach statistical significance compared to the single-agent treatments.
Researchers also reported no hemorrhages or fibrin deposits in any group, supporting the safety profile of the treatment.
The findings indicate that combining CBD with sodium propionate in a rectal enema may provide synergistic benefits for ulcerative colitis, warranting further research in clinical settings.